In August 2019, the European Union licensed the first ever haemoperfusion device aimed to reduce pathogens in the blood. The core of the adsorber consists of ultra-high molecular weight polyethylene beads with endpoint-attached heparin. These beads utilize pathogen inherent adhesion mechanisms to reduce pathogen load. So far, it is unknown whether the device has an effect on anti-infective drug concentrations. The aim of this study was to investigate the in vitro adsorption of multiple anti-infective drugs from human plasma.

中文翻译：

---

通过 Seraph® 100 Microbind® 亲和血液过滤器在体外消除抗感染药物。

2019 年 8 月，欧盟批准了首个旨在减少血液中病原体的血液灌流设备。吸附器的核心由带有末端连接肝素的超高分子量聚乙烯珠组成。这些珠子利用病原体固有的粘附机制来减少病原体负荷。到目前为止，尚不清楚该装置是否对抗感染药物浓度有影响。本研究的目的是研究人体血浆中多种抗感染药物的体外吸附。